About this Medicine article

Serum Periostin Levels in Asthma Patients in Relation to Omalizumab Therapy and Presence of Chronic Rhinosinusitis with Nasal Polyps by Novosad, Jakub; KrÄmová, Irena; BartoÅ¡, Vladimír; DrahoÅ¡ová, Marcela; Vaník, Petr; RÅ ̄Å3⁄4iÄková-Kirchnerová, Olga; TeÅl, Milan; Krejsek, Jan is a Medicine article available to read on EtoBox.

## Introduction The serum periostin level is a promising biomarker of type 2- high inflammation pattern of bronchial asthma. It has been proven that serum periostin levels decrease in response to systemic and inhaled corticosteroid (ICS) therapy. However, we have only limited knowledge about changes in serum periostin levels reflecting omalizumab (OMA) treatment and other variables, such as chronic rhinosinusitis with nasal polyps (CRSwNP). ## Aim To critically appraise clinically relevant parameters influencing periostin levels in asthma patients. ## Material and methods A pilot, cross-sectional, observational study to assess serum periostin levels of 48 asthma patients (38 treated by conventional therapy comprising ICS and 10 treated by ICS and OMA as an add-on therapy) with respect to asthma clinical traits, comorbidities and to other biomarkers of type 2-high asthma phenotype (total IgE, absolute and relative eosinophil count, eosinophilic cationic protein (ECP) and a fraction of exhaled NO (FeNO)). ## Results Serum periostin correlates with total IgE levels (Spearman rho = 0.364, __p__ = 0.025) in a subgroup of conventionally treated patients, and with eosinophil count (Spearm

Author

Novosad, Jakub; KrÄmová, Irena; BartoÅ¡, Vladimír; DrahoÅ¡ová, Marcela; Vaník, Petr; RÅ ̄Å3⁄4iÄková-Kirchnerová, Olga; TeÅl, Milan; Krejsek, Jan

Publisher

Termedia Sp. z.o.o.; Termedia Publishing House Ltd. (ISSN 2299-0046)

Published

2020

Language

EN

Field

Medicine (Health Sciences)